Clinical Impact of Down-regulated Plasma MiR-92a Levels in Non-Hodgkin's Lymphoma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Mar 9

PMID 21383985

Citations 47

Authors

Kazuma Ohyashiki

Tomohiro Umezu

Sei-ichiro Yoshizawa

Yoshikazu Ito

Michiyo Ohyashiki

Hisashi Kawashima

Masami Tanaka

Masahiko Kuroda

Junko H Ohyashiki

Affiliations

Soon will be listed here.

Abstract

Background: We undertook a study to evaluate the clinical relevance of miR-92a in plasma obtained from non-Hodgkin's lymphoma (NHL) patients, because the miR-17-92 polycistronic miRNA cluster plays a crucial role in lymphomagenesis and affects neo-angiogenesis.

Methodology/principal Findings: Plasma miR-92a values in NHL were extremely low (<5%), compared with healthy subjects (P<.0001), irrespective of lymphoma sub-type. The very low plasma level of miR-92a increased in the complete response (CR) phase but did not reach the normal range, and the plasma level was lower again in the relapse phase. Patients in CR or CR unconfirmed with a plasma miR-92a level of less than the cut-off level showed a significantly high relapse rate compared with patients with normalized plasma miR-92a level.

Conclusions/significance: The current results therefore indicate that the plasma miR-92a value could be a novel biomarker not only for diagnosis but also for monitoring lymphoma patients after chemotherapy.

Citing Articles

The effect of three types of water-based training protocols on thymus atrophy and specific indicators of cellular immune senescence in aged male rats.

Jahan-Mahin M, Askari R, Haghighi A, Khaiyat O Biogerontology. 2025; 26(1):44.

PMID: 39832052 PMC: 11747080. DOI: 10.1007/s10522-025-10183-5.

Exploratory screening for micro-RNA biomarkers in canine multicentric lymphoma.

Hammer S, Sprung J, Skor O, Burger S, Hofer M, Schwendenwein I Front Vet Sci. 2024; 11:1379146.

PMID: 38828367 PMC: 11141397. DOI: 10.3389/fvets.2024.1379146.

miR‑146a‑5p and miR‑191‑5p as novel diagnostic marker candidates for ovarian clear cell carcinoma.

Takamizawa S, Kojima J, Umezu T, Kuroda M, Hayashi S, Maruta T Mol Clin Oncol. 2024; 20(2):14.

PMID: 38264014 PMC: 10804375. DOI: 10.3892/mco.2023.2712.

Hypoxia-induced paclitaxel resistance in cervical cancer modulated by miR-100 targeting of USP15.

Nishi H, Ono M, Ohno S, Yamanaka Z, Sasaki T, Ohyashiki K Gynecol Oncol Rep. 2023; 45:101138.

PMID: 36714373 PMC: 9873580. DOI: 10.1016/j.gore.2023.101138.

Competitive Endogenous RNA Network Involving miRNA and lncRNA in Non-Hodgkin Lymphoma: Current Advances and Clinical Perspectives.

Fernandes M, Marques H, Teixeira A, Medeiros R Biomedicines. 2021; 9(12).

PMID: 34944752 PMC: 8698845. DOI: 10.3390/biomedicines9121934.

References

Iorio M, Croce C . MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27(34):5848-56. PMC: 2793003. DOI: 10.1200/JCO.2009.24.0317. View

Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T . Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010; 285(23):17442-52. PMC: 2878508. DOI: 10.1074/jbc.M110.107821. View

Pichiorri F, Suh S, Ladetto M, Kuehl M, Palumbo T, Drandi D . MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A. 2008; 105(35):12885-90. PMC: 2529070. DOI: 10.1073/pnas.0806202105. View

Cheson B, Pfistner B, Juweid M, Gascoyne R, Specht L, Horning S . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86. DOI: 10.1200/JCO.2006.09.2403. View

Inomata M, Tagawa H, Guo Y, Kameoka Y, Takahashi N, Sawada K . MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood. 2008; 113(2):396-402. DOI: 10.1182/blood-2008-07-163907. View

Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S . A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005; 65(21):9628-32. DOI: 10.1158/0008-5472.CAN-05-2352. View

Navarro A, Bea S, Fernandez V, Prieto M, Salaverria I, Jares P . MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. Cancer Res. 2009; 69(17):7071-8. DOI: 10.1158/0008-5472.CAN-09-1095. View

Garzon R, Calin G, Croce C . MicroRNAs in Cancer. Annu Rev Med. 2009; 60:167-79. DOI: 10.1146/annurev.med.59.053006.104707. View

Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C . Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood. 2003; 102(2):638-45. DOI: 10.1182/blood-2002-10-3257. View

10.

Hunter M, Ismail N, Zhang X, Aguda B, Lee E, Yu L . Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 2008; 3(11):e3694. PMC: 2577891. DOI: 10.1371/journal.pone.0003694. View

11.

Lawrie C, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S . Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 2009; 13(7):1248-60. PMC: 4496139. DOI: 10.1111/j.1582-4934.2008.00628.x. View

12.

Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, Suzuki Y . Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int. 2010; 60(5):351-7. DOI: 10.1111/j.1440-1827.2010.02526.x. View

13.

Nagel S, Venturini L, Przybylski G, Grabarczyk P, Schmidt C, Meyer C . Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2009; 50(1):101-8. DOI: 10.1080/10428190802626632. View

14.

Koster A, Raemaekers J . Angiogenesis in malignant lymphoma. Curr Opin Oncol. 2005; 17(6):611-6. DOI: 10.1097/01.cco.0000181404.83084.b5. View

15.

Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N . Serum microRNAs are promising novel biomarkers. PLoS One. 2008; 3(9):e3148. PMC: 2519789. DOI: 10.1371/journal.pone.0003148. View

16.

Han L, Witmer P, Casey E, Valle D, Sukumar S . DNA methylation regulates MicroRNA expression. Cancer Biol Ther. 2007; 6(8):1284-8. DOI: 10.4161/cbt.6.8.4486. View

17.

Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C . Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010; 107(5):677-84. DOI: 10.1161/CIRCRESAHA.109.215566. View

18.

Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler M . Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007; 109(10):4399-405. DOI: 10.1182/blood-2006-09-045104. View

19.

Resnick K, Alder H, Hagan J, Richardson D, Croce C, Cohn D . The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2008; 112(1):55-9. DOI: 10.1016/j.ygyno.2008.08.036. View

20.

Sander S, Bullinger L, Wirth T . Repressing the repressor: a new mode of MYC action in lymphomagenesis. Cell Cycle. 2009; 8(4):556-9. DOI: 10.4161/cc.8.4.7599. View